Daniel B. Soland

Daniel B. Soland is recorded as Board Member at Acadia Pharmaceuticals Inc (ACAD) since May 29, 2024. Earlier roles on record: Board Member at DBV Technologies S.A. (DBVT) until October 30, 2025, Board Member at DBV Technologies S.A. (DBVT) until September 18, 2025 and Board Member at KalVista Pharmaceuticals, Inc. until May 25, 2022. Acadia Pharmaceuticals Inc reported in an 8-K filed November 3, 2025 that Daniel B. Soland resigned as member and Chair of the Nominating and Corporate Governance Committee of the Board, effective October 30, 2025. DBV Technologies S.A. reported in an 8-K filed October 30, 2025 that Daniel B. Soland resigned as Board of Directors. DBV Technologies S.A. reported in an 8-K filed September 18, 2025 that Daniel B. Soland resigned as member of its Board of Directors, effective September 18, 2025. Equibles holds 4 filed executive changes naming Daniel B. Soland; each is listed under recent activity with its source filing. Acadia Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Acadia Pharmaceuticals Inc includes Catherine Owen Adams (CEO and Board Member), Stephen R. Biggar (Chairman and Board Member), Mark C. Schneyer (CFO) and 7 others.